Novelix Pharmaceuticals Limited has announced the reconstitution of its key board committees following a board meeting held on March 30, 2026, at the company's registered office in Hyderabad. The meeting, which commenced at 5:00 P.M. and concluded at 06:30 P.M., resulted in structural changes to three critical committees with immediate effect.

Committee Restructuring Details

The board approved the reconstitution of the Audit Committee, Nomination & Remuneration Committee, and Stakeholders Relationship Committee, ensuring compliance with regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Audit Committee Composition

The reconstituted Audit Committee features the following structure:

Nomination & Remuneration Committee Structure

The Nomination & Remuneration Committee maintains an identical composition to the Audit Committee:

Stakeholders Relationship Committee Formation

The Stakeholders Relationship Committee has been constituted with Sridevi Belide as Chairperson:

Regulatory Compliance

The reconstitution was conducted in accordance with Regulation 30 of SEBI (LODR) Regulations, 2015, with the company promptly notifying BSE Limited about the changes. The meeting was held at the company's registered office located at H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029.

Key Appointments

Janardhan Das Kabra, a Non-Executive Independent Director, has been appointed as Chairperson of both the Audit Committee and Nomination & Remuneration Committee. Sridevi Belide, a Non-Executive Non-Independent Director, leads the Stakeholders Relationship Committee. Mayuri Baidya serves as a member across all three committees, ensuring continuity and coordination between the various governance functions.

The changes took effect immediately from March 30, 2026, and the company has requested BSE Limited to disseminate this information through their official website for public disclosure.

Novelix Pharmaceuticals Limited has successfully completed a preferential share allotment to investor Mallela Venkataramna Reddy, with formal regulatory disclosures submitted to BSE Limited on February 17, 2026. The transaction involved the allotment of 3,30,000 equity shares representing 1.66% of the company's share capital, completed on February 12, 2026.

Regulatory Compliance and Documentation

The company has submitted comprehensive disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The formal intimation was filed by Whole-time Director Venkateshwarlu Pulluru to BSE Limited, where Novelix Pharmaceuticals shares are listed under scrip code 536565.

Shareholding Structure Changes

The preferential allotment has significantly altered the investor's stake in the company. The detailed shareholding pattern shows substantial increase in Reddy's ownership:

Company Capital Structure Enhancement

The preferential allotment has resulted in an expansion of Novelix Pharmaceuticals' equity share capital structure:

Corporate Governance and Transparency

The transaction demonstrates adherence to regulatory requirements with proper documentation submitted to both BSE Limited and the company's board of directors. Novelix Pharmaceuticals, formerly known as Trimurthi Limited, maintains its registered office in Hyderabad, Telangana, and operates under CIN L67120TG1994PLC018956.

This preferential allotment represents investor confidence in Novelix Pharmaceuticals' business prospects and provides the company with additional capital for operational and growth requirements while maintaining full regulatory compliance.